20. Adrenoleukodystrophy Clinical trials / Disease details
Clinical trials : 53 / Drugs : 88 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05200104 (ClinicalTrials.gov) | July 2022 | 6/1/2022 | Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | An Open-label Phase 2a Study to Assess the Pharmacokinetics and Pharmacodynamic of PXL065 Parameters After 12 Weeks of Treatment in Male Subjects With Adrenomyeloneuropathy (AMN) | ALD (Adrenoleukodystrophy) | Drug: PXL065 | Poxel SA | NULL | Not yet recruiting | 18 Years | 65 Years | Male | 12 | Phase 2 | NULL |